The pharmacological activity of DSP-6952, a novel compound was investigated, compared to that of clinically efficacious gastrointestinal (GI) prokinetic 5-hydroxytryptamine 4 (5-HT 4 ) receptor agonists. DSP-6952 had a strong affinity of Ki = 51.9 nM for 5-HT 4(b) receptor, and produced contraction in the isolated guinea pig colon with EC 50 of 271.6 nM and low intrinsic activity of 57%, similar to tegaserod and mosapride. In the development of the 5-HT 4 receptor agonists, cardiovascular risk was deliberately evaluated, because some related prokinetics were reported to cause with cardiovascular adverse events, such as ventricular arrhythmias or ischemia. DSP-6952 showed minimal effects up to 100 μM in human ether-a-go-go-related gene (hERG) channels or guinea pig cardiomyocytes. In telemetered conscious monkeys, DSP-6952 did not affect blood pressure or any electrocardiogram (ECG) up to 180 mg/kg, p.o.; however, DSP-6952 transiently increased heart rate, as well as in anesthetized dogs. The positive chronotropic effects of DSP-6952 were completely antagonized by a 5-HT 4 receptor antagonist, and another 5-HT 4 receptor agonist, TD-5108 also increased heart rate. These effects are considered a class effect seen in clinically developing and marketed 5-HT 4 receptor agonists, and have not been regarded as a critical issue in clinical use. DSP-6952 did not induce contraction in the rabbit coronary artery up to 100 μM, which differed from tegaserod or sumatriptan. These results show that DSP-6952 does not have cardiac ischemic risk via coronary vasoconstriction. In conclusion, DSP-6952 is a promising GI prokinetic compound with partial 5-HT 4 receptor agonistic activity as well as a favorable cardiovascular safety profile.
Introduction
Although the physiological role of 5-HT is so complicated by interacting with the different receptor subtypes (5-HT 1-7 ), 5-HT is rich in the gut, and in particular, the 5-HT 4 receptor is considered to play a pivotal role in the regulation of GI function (Baker, 2005; Gershon, 2005) . Neuronal 5-HT 4 receptors are located in the intrinsic primary afferent neurons within the gut wall, and activation of the 5-HT 4 receptor enhances the release of neurotransmitters from excitatory motor neurons, facilitating the peristaltic reflex in the GI tract. Actually, potent 5-HT 4 receptor agonists have been reported to exhibit well-defined GI prokinetic effects in both non-clinical and clinical studies, and thus could be applied for treatment of various GI functional disorders, such as irritable bowel syndrome with constipation (IBS-C), functional dyspepsia, and chronic constipation (De Maeyer et al., 2008; Shin et al., 2014) . piperidin-4-yl] methyl}morpholin-2-yl]methyl}− 2-methoxybemzamide hydrobromide dihydrate) ( Fig. 1) is a novel compound synthesized by Sumitomo Dainippon Pharma Co., Ltd. In this study, in vitro pharmacology of DSP-6952 for the 5-HT 4 receptor was characterized, comparing to that of other 5-HT 4 receptor agonists which were proved as a GI prokinetic agent.
For the purpose of ensuring the cardiovascular safety of DSP-6952 in the development as a 5-HT 4 receptor agonist, intensive safety pharmacology studies of DSP-6952 were carefully conducted. Although related 5-HT 4 receptor agonists have been competitively developed, some 5-HT 4 receptor agonists, such as cisapride and tegaserod, were reported to induce cardiovascular adverse effects, which resulted in their withdrawal from the clinical market (Tack et al., 2012) . Cisapride, a nonselective 5-HT 4 receptor agonist, is well known to exhibit strongly inhibitory effects on hERG current, leading to QT prolongation/ ventricular arrhythmias at supratherapeutic plasma concentrations in animals and patients (Ando et al., 2005; Carlsson et al., 1997; Drolet et al., 1998; Shiotani et al., 2005; Toyoshima et al., 2005; Wysowski and Bacsanyi, 1996) . Although tegaserod was once approved in many countries for treatment of IBS-C or chronic idiopathic constipation, tegaserod was reported to have been associated with ischemic cardiovascular adverse events, which resulted in its withdrawal from most clinical market (Pasricha, 2007; Tack et al., 2012) . Whereas mechanisms for the ischemic cardiovascular events of tegaserod are not fully elucidated, a suggested mechanism involves an off-target interaction with 5-HT 1B/1D or 5-HT 2A receptor in the coronary arteries (Beattie et al., 2004; De Maeyer et al., 2008; Smith et al., 2008) . Therefore, for risk assessment of prolonged cardiac repolarization of DSP-6952, whole-cell patch clamp tests using hERG-transfected Chinese hamster ovary (CHO)-K1 cells and isolated guinea pig ventricular myocytes were performed. A telemetry study on conscious monkeys evaluated the cardiac ECG, heart rate, and blood pressure in parallel with measurement of plasma concentration of DSP-6952. A comparative follow-up study of the cardiovascular effects between DSP-6952 and TD-5108 (Velusetrag) in anesthetized dogs was also carried out, to explore mechanism of the increased heart rate induced by DSP-6952 in the telemetry study. Furthermore, an in vitro experiment using the isolated coronary arteries was performed, to investigate potential risk of the ischemic cardiovascular adverse events via coronary constriction.
Materials and methods
All experimental procedures involving animals use and care were reviewed and approved by the Institutional Animal Care and Use Committee of Sumitomo Dainippon Pharma Co., Ltd.
Test compounds
DSP-6952 (4-amino-5-chloro-N-{[(2S)− 4-{[1-(hydroxyacetyl)piperidin-4-yl] methyl}morpholin-2-yl]methyl}− 2-methoxybemzamide hydrobromide dihydrate), tegaserod, prucalopride, mosapride citrate hydrate (mosapride), TD-5108 (1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid ((1S,3R,5R)− 8-[(R)− 2-hydroxy-3- (methanesulfonyl-methyl-amino) propyl]− 8-aza-bicyclo [3.2.1]oct-3-yl) amide), GR113808 (1-(2-((methylsulphonyl)amino)ethyl)− 4-piperidinyl)methyl-1-methyl-1H-indole-3-carboxylate), and SB-207266 (N-[(1-butyl-4-piperidinyl) methyl]− 3,4-dihydro-2H-[1,3]-oxazino[3,2-indole-10-carboxamide) were synthesized at Sumitomo Dainippon Pharma Co., Ltd. 5-HT (serotonin creatinine sulfate complex, SigmaAldrich, St Louis, MO, USA),
Life Sciences, Inc., Plymouth Meeting, PA, USA), Sumatriptan (GlaxoSmithKline K.K, Ibaraki, Japan), GR127935 (N-[4-methoxy-3-(4-methyl-1-piperizinyl)phenyl]− 2'-methyl-4'-(5-methyl-1,2,4-oxadiazole-3-yl, Sigma-Aldrich), and U-46619 (9,11-dideoxy-11α,9α-epoxy-methano-prostaglandin F 2α ) (CALBIOCHEM, Nottingham, UK) were commercially purchased.
5-HT 4 receptor binding study
Membranes prepared from cells expressing each human recombinant receptor or guinea pig tissue were used in the receptor binding assay. CHO cells stably transfected with the human 5-HT 4(a) , 5-HT 4(b) , or 5-HT 4(c) receptor splice variants were constructed in our laboratories with a modified method (Bender et al., 2000) . The guinea pig 5-HT 4 receptor was the cell membrane homogenates from the striatum in male Hartley guinea pigs (Japan SLC, Inc., Shizuoka, Japan). The 5-HT 4 receptor radioligand membrane binding assays were conducted as previously described (Bender et al., 2000; Grossman et al., 1993 (Cheng and Prusoff, 1973) . The binding data were calculated from the average of triplicate measurements.
In vitro contractile response in the guinea pig distal colon
Male Hartley guinea pigs were euthanized by decapitation, and the distal colon (approximately 10 cm from the anus) was removed and placed in a bathing solution, Krebs-Henseleit physiological buffer consisted of 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 118.1 mM NaCl, 11.1 mM D-(+ )-glucose, 25 mM NaHCO 3 , and 2.6 mM CaCl 2 containing granisetron (1 μM; to block 5-HT 3 receptor), methysergide (1 μM; to antagonize 5-HT 1 and 5-HT 2 receptors), and indomethacin (1 μM; to inhibit prostaglandin synthesis). Sections of the longitudinal muscle with myenteric plexus (LMMP) were dissected as described by Wardle and Sanger (1993) . The preparation sections were suspended longitudinally under an initial tension of approximately 1 g in an organ bath filled with the bathing solution. Changes in colonic isometric forces were evaluated by the Magnus method using a 3-cm LMMP preparation hung on a transducer (FD Pick-up, TB-611T, Nihon Koden, Co., Tokyo, Japan). Contractile response was measured via an amplifier Nihon Koden, Co.) , and recorded on a chart recorder. The guinea pig distal colon LMMP preparations were first exposed to 5-HT, to stabilize contractile response. Each tissue was exposed to 3 × 10 −7 M of 5-HT four times, until consistent responses were obtained. After the fourth 5-HT challenge, the tissue was washed, and a 5-HT cumulative concentrationresponse curve was constructed with increasing concentrations of 5-HT (first curve). For cumulative dosing, a new concentration was applied at the instance of the maximal effect of the previous concentration. After obtaining maximum concentration with the final 5-HT concentration, the tissues were washed, and allowed to be stabilized for approximately 1 h. Next, a cumulative concentration-response curve for each test compound was constructed with increasing concentrations of the test compound (second curve). In the experiment to determine the test compound cumulative concentration-response curve (second curve), the contractile response induced by each test compound at each concentration was expressed as a percentage of maximum contractile response in each LMMP preparation. The contractile response (%) induced by each test compound at each concentration was expressed as the mean value, and half maximal effective concentration (EC 50 ) values were calculated. The EC 50 value was determined as an estimated value with a 95% confidence interval. To estimate the intrinsic activity of each test compound, the contractile response at each concentration was expressed as a percentage of the maximum contractile response in the 5-HT cumulative concentration-response curve (first curve) for each preparation. Intrinsic activity was determined as the maximum test T. Tsubouchi et al. European Journal of Pharmacology 826 (2018) 96-105 compound-induced response, and was expressed as a percentage of the maximum 5-HT-induced response.
In vitro cardiac safety studies
The hERG currents were measured at room temperature using the whole-cell configuration of the patch-clamp technique. Effects of DSP-6952 and a positive control, E-4031 were evaluated in five hERGtransfected CHO-K1 cells (Cytomyx Ltd., Cambridge, UK). The cover slips seeded with the cells were transferred to a recording chamber. In a constant perfusion, a glass electrode with a resistance of 5.1-8.9 MΩ was used. The external solution consisted of 137 mM NaCl, 4 mM KCl, 10 mM HEPES, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM glucose with pH adjusted at 7.4 using NaOH. The internal solution consisted of 130 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 10 mM HEPES, and 5 mM MgATP with pH adjusted at 7.2 using KOH. The obtained hERG tail currents were recorded using a patch-clamp software (pCLAMP10, Axon Instruments, Inc., Union City, CA, USA) and a patch-clamp amplifier (Multiclamp 700 A, Axon Instruments, Inc.). After a stable wholecell current was achieved, the cells were treated with the test compound at different concentrations. The stimulant voltage protocol involved a continuous step pulse from the holding potential of − 80 mV to + 40 mV for 1 s, and then repolarizing to − 50 mV for 2 s with intervals of 15 s. All data were expressed as relative values (%) to that before treatment, and the inhibition rate (%) at each concentration of the test compound was calculated as the ratio of the relative value in the test compound-treated group to that in the vehicle-treated group. The half maximal inhibitory concentration (IC 50 ) of DSP-6952 was calculated from the inhibition rates at different concentrations by a logistic method using non-clinical statistical analysis system (Stat Preclinica, version 1.0, Takumi Information Technology Inc., Tokyo, Japan; SAS System, version 9.1, SAS Institute Inc., Cary, NC, USA).
In addition, the effects of DSP-6952 on the cardiac action potentials were measured in the isolated guinea pig cardiomyocytes. Male Hartley guinea pigs were anesthetized via intraperitoneal administration of sodium pentobarbital at 30-40 mg/kg, and then implanted with a cannula into the cardiac aorta under artificial ventilation. The heart was isolated and perfused with 0.019% collagenase solution in Langendorff system. Then, the ventricular myocytes were isolated by mild agitation. The cardiomyocyte action potentials were recorded using the patch clamp technique by applying continuous stimulus pulse (2-3 nA, 2-3 ms, 0.2 Hz). HEPES-Tyrode solution was used for a perfusate. The action potentials were measured under the current-clamp condition via a patch-clamp amplifier (Multiclamp 700B, Axon Instruments, Inc.) using the patch-clamp software, Clampex and MultiClamp Commander (pCLAMP10, Axon Instruments, Inc.). The experiment was conducted at physiological temperature. DSP-6952 was prepared in water, and applied with 1000-fold dilution to the in vitro experimental systems. E-4031 was used as a positive control, and the action potential amplitude (APA) and action potential duration at 90% repolarization (APD 90 ) were evaluated using the software, Clampfit (pCLAMP10, Axon instruments, Inc.).
In vivo telemetry study using cynomolgus monkey
The objective of this experiment was to evaluate overall cardiovascular effects of DSP-6952 in conscious and unrestrained telemetered cynomolgus monkeys, which have enough backgrounds data and demonstrated QT prolongation by cisapride (Ando et al., 2005) . Four male cynomolgus monkeys (Macaca fascicularis, bred in Vietnam) aged 3-4 years and weighing 3.3-3.9 kg were purchased from LSI Medience Corp. (Kashima, Japan). The animals were maintained in individual stainless steel cage (W: 698 mm × D: 1048 mm × H: 808 mm, floor are: 7315.04 cm 2 ) in a standard environment (temperature: 21-28°C, relative humidity: 35-75%, lighting period: 7:00-19:00, air ventilation: 10-20 changes/h). Pellet diet was provided at approximately 100 g/ animal/day, and drinking water was given ad libitum. First, a telemetry transmitter (TL11M2-D70-PCT, Data Sciences International Inc., St Paul, MN, USA) was implanted in the monkeys for measurement of the cardiovascular parameters. The animals were anesthetized using intramuscular administration of ketamine hydrochloride and xylazine hydrochloride at 5-25 and 1-3 mg/kg, respectively. The telemetry transmitter was implanted in the abdominal cavity, and a catheter containing a built-in pressure sensor connected to the transmitter was inserted into the femoral artery for measurement of the arterial blood pressure. Electrodes for ECG monitoring were implanted subcutaneously on right side of the chest and left side of the abdomen. Prior to the study, the animals were allowed to recover from the surgery for more than 12 days. Because it was confirmed that the animals implanted with the telemetry transmitter were healthy, and showed normal cardiovascular parameters, all the animals were employed in this experiment. Although the dosing formulations were a suspension, these formulations were confirmed to be homogenous and stable for 15 days in a refrigerator and for 6 h at room temperature. The prepared dosing formulations were completed to use within the expiration period. Before administration of DSP-6952, the baseline values of the ECG parameters (PQ interval, QRS duration, corrected QT (QTc)), heart rate, and blood pressure were measured using the telemetry system (NOTOCORD-hem 3.5, NOTOCORD SYSTEMS SAS, Croissy Sur Seine, France). After obtaining stable cardiovascular parameters, DSP-6952 was administered at 10:10-10:19 a.m. to each animal by oral gavage at five doses of 0 (vehicle control), 6, 20, 60, or 180 mg/kg once daily, each separated by a wash-out period of 7 days. 0.5 w/v% methylcellulose was used as a vehicle, and a dosing volume was 5 ml/kg. Dose volume was calculated based on body weights measured each week. After administration of the vehicle or DSP-6952, the cardiovascular parameters were continuously recorded for over 24 h. For evaluation of the cardiovascular parameters, analyzing time points were set before and at 1, 3, 5, 7, and 24 h after administration. In the analysis of heart rate and blood pressure, mean values for 1 min were acquired near the scheduled time points, when noise by body movement was not found. As for the ECG parameters, mean values were acquired from five ECG waveforms of the 1 min period. Simultaneously, the general behavior was continuously monitored using a video monitoring system. All parameters were measured in conscious and unrestrained states. QTc was calculated using Bazett's correction formula (QTc = QT / (RR) 1/2 ). The cardiovascular parameters were statistically analyzed based on the 2 factors of tested group and time by univariate repeated-measures analysis as a split-plot design (EXSUS: Repeated Measurement ANOVA), followed by a multiple-comparison test to compare the values at each analyzing time point with those of the vehicle-treated group. In addition, approximately 0.5 ml of blood was collected from the cephalic or the lateral saphenous vein at the above analyzing time points, and the plasma was separated by centrifugation, to measure the plasma concentration of DSP-6952. The plasma concentration of DSP-6952 was measured by a validated liquid chromatography/tandem mass spectrometry method. The plasma concentration and the related toxicokinetic parameters were expressed as the mean and standard deviation (S.D.). After completion of the study, all the animals were back to home cages in preparation for reuse in other studies.
In vivo anesthetized dog study
The objective of this experiment was to evaluate the direct chronotropic effects on the heart, and explore the mechanism using the anesthetized dogs, which have enough background data. Male Beagle dogs weighing 8.4-12.4 kg, were obtained from Covance Research Products Inc. (Kalamazoo, MI, USA). Two to 3 healthy animals were randomly assigned to 3 experimental groups (vehicle control, DSP-6952, or TD-5108-treated groups, total number of animals used; 7). The animals were anesthetized initially with intravenous injection of sodium thiopental (Ravonal, Nipro ES Pharma Co., Ltd., Osaka, Japan). After endotracheal intubation, animals were anesthetized via inhalation of 1-3% isoflurane (Isoflu, Sumitomo Dainippon Pharma Co., Ltd.) using a volume-limited ventilator (SN-480-3, Shinano Seisakusyo, Tokyo, Japan). Tidal volume and respiratory rate were set at 20 ml/kg and 20 strokes/min, respectively. Heart rate and arterial blood pressure were measured using a pressure transducer (DX-100, Nihon Koden Co.) connected to a catheter, which was inserted into the femoral artery and positioned in the abdominal aorta. These parameters were continuously recorded using a polygraph system (RM-7000, Nihon Koden Co.), and analyzed using a software (FLUCLET, version 4.0, Sumitomo Dainippon Pharma Co., Ltd.). Rectal temperature was continuously monitored and kept at around 37.5°C, using a heating pad and an aluminum foil blanket. After obtaining stable hemodynamic parameters, DSP-6952 and TD-5108 were intravenously infused at 1.3 and 1 mg/kg, respectively, which were selected enough to cause increase in heart rate. Each test compound solution in physiological saline was freshly prepared just before use, and the solution was injected at a dosing volume of 1 ml/kg over 10 min by a syringe pump (CFV-3200, Nihon Koden Co.). Dose volume was calculated based on body weights measured in the morning of the experimental date. Thirty min after start of the infusion, a selective 5-HT 4 receptor antagonist, SB-207266 was intravenously administered at a dose of 1 mg/kg over 1 min. Intravenous or subcutaneous administration with doses of 0.1-1 mg/kg of SB-207266 was suggested to exert the peripheral 5-HT4 receptor antagonistic activity in animal models (Armstrong et al., 2006; Sanger et al., 1998; Wardle et al., 1996) . Each parameter was expressed as a percentage change over time, compared with the pre-value. After completion of the study, all animals were recovered from the anesthesia, and back to home cages.
In vitro contractile response in the rabbit coronary artery
Male Japanese white rabbits (kbl: JW, Kitayama Labes, Co., Ltd., Ina, Japan) were anesthetized via intravenous administration of sodium pentobarbital at 50 mg/kg, and exsanguinated to death by cutting the carotid artery. The heart was immediately isolated and transferred to Krebs-Henseleit buffer gassed with 95% O 2 and 5% CO 2 . In the KrebsHenseleit buffer, the left coronary artery was isolated and cleared from the surrounding tissues. The artery without any damage was cut into about 2-mm wide rings. The endothelium was denuded by rubbing the inner surface of the vessel with a flexible stainless wire. Each ring segment was mounted into a tissue chamber under a resting tension of 500 mg, and the isometric tension of the coronary artery rings was measured. Contraction of the coronary artery rings was recorded on a chart recorder (SR6221, Graphtec Corp., Tokyo, Japan) by a force displacement transducer (TB-611T or TB-612T, Nihon Koden Co.) and a preamplifier (LC210, Unipulse Corp., Tokyo, Japan). The chamber was filled with Krebs-Henseleit buffer bubbled with 95% O 2 and 5% CO 2 . After stabilization for over 45 min, 40 mM of KCl was repeatedly applied to the coronary artery ring at intervals of 30 min. After contractions were stably induced by 40 mM of KCl, it was confirmed whether KCl caused concentration-dependent contractions by cumulative application of KCl at 10, 20, and 40 mM. Over the next 30 min, cumulative application of successive concentrations of the test compound was carried out with stock solutions. The stock solutions of each test compound were freshly prepared in dimethyl sulfoxide just before use. A certain concentration of the test compound was applied after effects of the lower concentration of the test compound on the rings were confirmed to be no effects or reach a plateau. The highest or lowest amplitude of the contraction induced by each concentration of the test compound was measured with a slide caliper. The concentrations of sumatriptan were set 1 × 10 −9 to 1 × 10 −5 M, by referring papers (Ellwood and Curtis, 1997; Ishida et al., 2001) . DSP-6952, TD-5108, and tegaserod were applied up to enough high concentration of 10-100 μM. Although TD-5108 was used as a selective 5-HT 4 receptor agonist in this experiment, pEC 50 value for human 5-HT 4 receptor was demonstrated 8.3 (Smith et al., 2008) . The contraction was expressed as the relative amplitude (%) to the maximum amplitude of contraction triggered by 20 mM of KCl. After the final concentration of 10 μM of tegaserod or sumatriptan was applied, a selective 5-HT 1B/1D receptor antagonist, GR127935 was applied to the ring strip at concentration of 0.01-0.1 μM, in order to explore the mechanism of coronary artery contraction. According to some papers, 0.001-0.1 μM of GR127935 was sufficient to block the contractile 5-HT 1B/1D receptors in the isolated coronary arteries (Bouchelet et al., 2000; Ellwood and Curtis, 1997; Ishida et al., 2001; Terrón, 1996) . In addition, concentration-response curves were constructed for tegaserod and sumatriptan in the presence of a certain concentration of a thromboxane A 2 (TXA 2 ) analogue, U-46619. The concentration of U-46619 was adjusted with 3 × 10 −7 to 3 × 10 −3 μM in the respective coronary artery ring to cause approximately 10% of the maximal contraction in the concentration-response curve of U-46619. These concentrations of U-46619 were reported enough to mediate 5-HT-induced contraction in the human coronary artery (Chester et al., 1993a) .
Results

5-HT 4 receptor binding study
In the saturation binding experiment with human recombinant 5-HT 4 receptors, [ (Table 1) , which is almost comparable to that in prucalopride. Whereas tegaserod had the strongest affinity for the 5-HT 4 receptors, mosapride had a comparatively moderate affinity.
In vitro contractile response in the guinea pig distal colon
In the guinea pig distal colon LMMP, it was confirmed that 5-HT Table 1 Ki values for DSP-6952 and other reference compounds at human 5-HT 4 receptors stably transfected in CHO cells or 5-HT 4 receptor in the guinea pig striatum.
Test compound
Ki ( The percentage inhibition of specific binding was determined. Ki values were derived from three independent experiments conducted in duplicate.
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induced monophasic and concentration-dependent contraction through the 5-HT 4 receptor activation, since the bating solution included appropriate concentrations of granisetron (5-HT 3 receptor antagonist) and methysergide (5-HT 1 and 5-HT 2 receptors antagonist). As shown in Fig. 2 , DSP-6952, tegaserod, prucalopride, and mosapride also induced concentration-dependent contractions in the colon LMMP. The EC 50 values were as shown in Table 2 . The intrinsic activity relative to the 5-HT induced maximum response is 83% in prucalopride, whereas the intrinsic activities are comparatively small, 57%, 49%, and 29% for DSP-6952, tegaserod, and mosapride, respectively.
In vitro cardiac safety studies
As shown in Table 3 , DSP-6952 inhibited the hERG current in a concentration-dependent manner with an IC 50 of 65.4 μM. This experimental system was validated by confirming that E-4031, a positive control, markedly inhibited the hERG current at a concentration of 0.3 μM. In addition, the action potential in the guinea pig ventricular myocytes was evaluated (Table 4) . Although it was confirmed that E-4031 caused a prolongation in APD 90 by 34% at a concentration of 0.1 μM, DSP-6952 had no effect on APA or APD 90 at concentrations up to 100 μM.
In vivo telemetry study using cynomolgus monkey
The effects of oral administration of DSP-6952 on the cardiovascular system were evaluated in an in vivo telemetry study using cynomolgus monkeys (Fig. 3) . Regarding the ECG parameters about PQ interval, QRS duration, or QTc, no statistically significant changes were detected in the DSP-6952-treated groups at doses up to 180 mg/kg, compared with those in the vehicle-treated group. The blood pressure was not significantly affected by DSP-6952 at doses up to 180 mg/kg. Although no statistically significant differences in heart rate were detected for up to 24 h after administration of DSP-6952 at 6, 20, and 60 mg/kg, a tendency of dose-dependent increase in heart rate was observed transiently at 1 h after administration, starting from the dose of 20 mg/kg. A significant increase in heart rate occurred at 1 h after administration of DSP-6952 at a dose of 180 mg/kg. In addition, at the highest dose of 180 mg/kg, the PQ interval was transiently and slightly shortened, which was secondary to the increase in heart rate. These values recovered to the normal ranges at 3-7 h after administration. Results of the plasma concentrations of DSP-6952 are shown in Table 5 . The plasma concentration increased with dose with mean maximum plasma concentration (C max ) values of 723, 4840, 19100, and 98100 ng/ml at 6, 20, 60, and 180 mg/kg, respectively. Mean time to reach the C max (t max ) values were 5.5, 2.5, 1.0, and 1.0 h at 6, 20, 60, and 180 mg/kg, respectively. Throughout the observational period, no abnormalities in the general behavior or condition, including emesis or diarrhea, were observed in any group.
In vivo anesthetized dog study
Because DSP-6952 resulted in a significant increase in heart rate at a high dose of 180 mg/kg in the telemetered monkey, a follow-up study was conducted in beagle dogs anesthetized with isoflurane. An intravenous infusion of 1.3 mg/kg of DSP-6952 in the anesthetized dogs resulted in increases in heart rate and blood pressure (Fig. 4) . The positive chronotropic effects of DSP-6952 were completely antagonized by an intravenous bolus injection of the selective 5-HT 4 receptor antagonist, SB-207266 at 1 mg/kg. These results suggested that the increase in heart rate by DSP-6952 occurred through 5-HT 4 receptor activation. This suggested mechanism was consistent with the findings that another selective 5-HT 4 receptor agonist, TD-5108 caused an increase in heart rate and blood pressure, which was completely antagonized by the same dose of SB-207266. It was confirmed that effects of DSP-6952 The contractile response induced by each test compound at each concentration was expressed as percentage of maximum contractile response in each preparation. The EC 50 value of contractile response was determined as an estimated value with a 95% confidence interval. Intrinsic activity was determined as maximum test compound-induced response, and expressed as a percentage of the maximum 5-HT-induced response. n indicates number of experiments. T. Tsubouchi et al. European Journal of Pharmacology 826 (2018) 96-105 on the hemodynamics were completely inhibited by pretreatment of SB-207266 as well, and SB-207266 alone did not affect heart rate and blood pressure (Supplemental Fig.) .
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In vitro contractile response in the rabbit coronary artery
The effects of the test compounds on the coronary artery isolated from rabbits were evaluated for assessment of their cardiac ischemic potential. As shown in Fig. 5 , a positive control, sumatriptan caused strong contraction of the coronary artery in a concentration-dependent manner. Tegaserod induced coronary artery contraction in a concentration-dependent manner from 1 nM to 10 μM. The contractile response to tegaserod was much weaker than that to sumatriptan. In addition, it was noteworthy that 2 of 7 coronary artery rings showed relatively much smaller contractions in the treatment with tegaserod at concentrations up to 10 μM. To the contrary, DSP-6952 and TD-5108 did not induce coronary artery contraction at concentrations up to 100 μM. A selective 5-HT 1B/1D receptor antagonist, GR127935 was applied to the coronary artery rings after treatment with the final concentration of 10 μM of tegaserod or sumatriptan. The coronary artery contraction induced by tegaserod and sumatriptan was strongly antagonized by 0.01 or 0.1 μM of GR127935 (Fig. 6 ). In addition, it was 
Time after administration (h) Time after administration (h)
Heart rate (bpm)
Blood pressure (mmHg) Fig. 3 . Effects of DSP-6952 on ECG parameters (PQ interval, QRS duration, QTc), heart rate, and blood pressure in conscious and unrestrained cynomolgus monkeys. The telemetry monitoring was performed continuously before and after oral administration of DSP-6952. The vertical axis indicates the actual value (ms, beats per min, or mmHg) in ECG parameters, heart rate, or arterial blood pressure over time. The horizontal axis indicates time after administration (h). Each point and bar represents the mean and S.D. of 4 animals. * p < 0.05 vs the vehicle-treated group, repeated measurement ANOVA followed by Dunnett's multiple comparison test.
Table 5
Plasma concentration of DSP-6952 after oral administration to conscious telemetered cynomolgus monkeys.
Dose (mg/kg) Index Plasma concentration at the time after administration (ng/ml) C max (ng/ml) t max (h) AUC 0-24 (ng·h/ml) The lower limit of quantification (LLOQ) of DSP-6952 was determined to be 0.5 ng/ml. AUC 0-24 was calculated as the area under the plasma concentration time curve from 0 to 24 h after administration according to the Linear trapezoidal rule. Values are calculated from 4 animals.
T. Tsubouchi et al. European Journal of Pharmacology 826 (2018) 96-105 examined whether the TXA 2 analogue, U-46619 might mediate the contractile response to tegaserod or sumatriptan. In the presence of 3 × 10 −7 to 3 × 10 −3 μM of U-46619, the concentration-contractile response curves of tegaserod and sumatriptan showed a leftward shift to lower concentrations, compared with those in the absence of U-46619 (Fig. 7) . In particular, the maximal amplitude of coronary artery contraction induced by tegaserod at different concentrations was augmented in the presence of U-46619, compared with that in the absence of U-46619. The augmentation of the concentration-contractile response curve leftwarded shift and the contraction amplitude was larger with tegaserod than that with sumatriptan.
Discussion
The presence of multiple 5-HT 4 receptors has been confirmed with five C-terminal splice variants of the human 5-HT 4 receptor and 10 different isoforms (Blondel et al., 1998; Kaumann and Levy, 2006) . Among these receptors, 5-HT 4(a) , 5-HT 4(b) , and 5-HT 4(c) receptors are highly expressed throughout the GI tract in animals and human (Ito et al., 2003; Pindon et al., 2002) . DSP-6952 had a strong binding for all the 5-HT 4 receptors as well as that in the guinea pig striatum. Tegaserod, or marketed compounds of prucalopride and mosapride also showed various affinities for the 5-HT 4 receptors, which are consistent with the literature (Mine et al., 1997; Smith et al., 2008; Vickery et al., 2007) . To evaluate the agonistic activity of the 5-HT 4 receptors, the contractile response was determined using the isolated guinea pig colon LMMP in the presence of 5-HT 1 , 5-HT 2 , and 5-HT 3 receptor antagonists, comparing with the maximum contraction of 5-HT. DSP-6952 and other reference compounds produced concentration-dependent contraction in the LMMP. In addition, it is characteristic that DSP-6952 exhibited low intrinsic activity of 57% relative to the 5-HT-induced maximum response, similar with tegaserod or mosapride, whereas prucalopride showed almost full intrinsic activity. Although it is considered that DSP- 
Sumatriptan (11)
Tegaserod ( T. Tsubouchi et al. European Journal of Pharmacology 826 (2018) 96-105 6952 can exert the partial 5-HT 4 receptor agonistic action, like tegaserod or mosapride, it has been demonstrated that the partial 5-HT 4 receptor agonist, DSP-6952 improved GI motility and inhibited visceral hypersensitivity in animals (Mine et al., In press ). Regarding to other relevant receptors reported in clinically developing or marketed gastroprokinetics, a preliminary off-targeted binding assay demonstrated that DSP-6952 had negligible affinity at 10 μM for human dopamine D 1 /D 2 , rat γ-aminobutyric acid (GABA) A/B , human muscarinic M 1 /M 2 , opioid δ/κ/μ , human 5-HT 1A/1B/1D and human 5-HT 3 receptors or rat potassium/sodium ion channels in duplicate.
To ensure the cardiovascular safety of DSP-6952, intensive safety pharmacology studies of DSP-6952 were conducted. In a hERG current inhibition assay, DSP-6952 showed minimal inhibition with an IC 50 of 65.4 μM. The hERG IC 50 was approximately 240-fold higher than the EC 50 of 271.6 nM in the isolated guinea pig colon. The study using the guinea pig cardiomyocytes demonstrated that DSP-6952 did not induce prolongation of APD 90 at a concentration of 100 μM. Furthermore, an in vivo telemetry study in conscious monkeys revealed no QTc or QRS prolongation up to the total C max of 98100 ng/ml (215.6 μM) at 180 mg/kg, p.o. Based on pharmacokinetic studies of DSP-6952, this plasma free concentration of DSP-6952 was predicted to be approximately 360-fold higher than the in vitro EC 50 described previously. At present, there are no evidence that DSP-6952 concentration is high especially in the heart or increasing in the plasma by repeating dosing. QT prolongation is generally known as a surrogate marker for ventricular arrhythmias. Taken together, it can be concluded that DSP-6952 does not have the potential risk for ventricular arrhythmias through QT prolongation. In contrast, a related gastroprokinetic, cisapride has a small safety margin of less than 10-fold between its strong hERG current inhibition and its therapeutic concentration, resulting in withdrawal from the market owing to the ventricular arrhythmias (De Maeyer et al., 2008; Drici and Barhanin, 2000; Redfern et al., 2003; Walker et al., 1999) . Although both DSP-6952 and cisapride have a benzamide structure, this structure is not always responsible for the hERG channel inhibition or QT prolongation. For instance, clinical evidence revealed that renzapride and ATI-7505 (naronapride) with the benzamide structure did not induce QT prolongation (Camilleri et al., 2007; Meyers and Hickling, 2007) .
In the telemetered monkey study, DSP-6952 showed a transient and dose-dependent increase in heart rate with statistical significance at 180 mg/kg, p.o. The total C max of DSP-6952 (at 60 mg/kg, a dose with no statistically-significant effect on heart rate) was 19,100 ng/ml, and the plasma free C max was predicted to be approximately 50-fold higher than the EC 50 in the isolated guinea pig colon described previously. In a follow-up study using anesthetized dogs, DSP-6952 similarly induced an increase in heart rate, possibly via a direct action on the cardiac 5-HT 4 receptors, because the increase in heart rate by DSP-6952 was completely antagonized by the selective 5-HT 4 receptor antagonist, SB-207266. 5-HT 4 receptors are present in both the atria and ventricles, wherein 5-HT 4 receptor activation might be associated with tachycardia (Hegde and Eglen, 1996; Kaumann and Levy, 2006) . Because selective 5-HT 4 receptor agonists, TD-5108 and prucalopride (European medicines agency, 2009) also caused tachycardia in the anesthetized dog, the positive chronotropic effects of DSP-6952 are considered a class effect of 5-HT 4 receptor agonists. Prucalopride was approved in Europe for the treatment of chronic idiopathic constipation, and to date, appears to have no cardiovascular liability in clinical use (Camilleri, 2012; Tack et al., 2012) . The marketed prucalopride as well as the clinically developing 5-HT 4 receptor agonists, TD-5108, renzapride, and ATI-7505, had weak or no effects on heart rate in clinical trials (Camilleri et al., , 2007 Manini et al., 2009; Mendzelevski et al., 2012; Meyers and Hickling, 2007) . Therefore, it is unlikely that the transient increase in heart rate induced by DSP-6952 in animals causes serious concerns in the therapeutic dose ranges. Although some clinical studies showed that prucalopride with full agonistic activity for 5-HT 4 receptor caused small and transient increase in heart rate (Tack et al., 2012) , DSP-6952 with partial 5-HT 4 receptor agonistic activity might be helpful for less increase in heart rate in the clinical use. In fact, mosapride with partial 5-HT 4 receptor agonistic activity showed no effects on heart rate in healthy volunteers (Endo et al., 2002) . Nonclinical studies also suggested that the partial 5-HT 4 receptor agonists have a good balanced GI effects without cardiac effects (De Maeyer et al., 2006) .
Tegaserod was reported to have been associated with ischemic cardiovascular events, such as myocardial infarction or unstable angina, in a retrospective analysis of clinical studies (Pasricha, 2007; Tack et al., 2012) . The mechanism responsible for the ischemic cardiovascular events of tegaserod was not completely elucidated, and there are several studies denying these adverse cardiovascular outcomes (Beattie et al., 2013; Chan et al., 2009; Higgins et al., 2012; Loughlin et al., 2010) . However, a suggested mechanism involves constriction in the coronary arteries through off-targeted binding to 5-HT 1B/1D , or 5-HT 2 receptor (De Maeyer et al., 2008; Tack and Müller-Lissner, 2009 ). Sumatriptan was reported to cause chest symptoms mimicking angina pectoris up to 15% of patients in the treatment of migraine, and these chest symptoms were thought to be caused by coronary vasoconstriction (Bax and Saxena, 1993; Chester et al., 1993b; Plosker and McTavish, 1994; Visser et al., 1996) . It was shown that sumatriptan induced contractions in the isolated rabbit coronary arteries owing to 5-HT 1B/1D receptors activation (Ellwood and Curtis, 1997; Ishida et al., 2001) . A similar mechanism was presumed for tegaserod, and thus, this experimental system was considered appropriate for evaluation of the cardiac ischemic risk of DSP-6952, comparing with tegaserod and TD-5108. In our study, tegaserod induced a concentration-dependent contraction of the rabbit coronary artery, although the contractile response to tegaserod was much weaker than that to sumatriptan. To the contrary, DSP-6952 did not induce coronary artery contraction at an extremely high concentration of up to 100 μM. Another selective 5-HT 4 receptor agonist, TD-5108 caused little coronary artery contraction up to 100 μM, which indicated that on-targeted 5-HT 4 receptor activation is not associated with induction of the coronary artery contraction. A selective 5-HT 1B/1D receptors antagonist, GR127935 antagonized the coronary artery contractions by tegaserod and sumatriptan, which suggested that the coronary artery contractions might be due to 5-HT 1B/ 1D receptors activation. As described previously, the preliminary offtargeted binding assay revealed that DSP-6952 has negligible binding affinities to 5-HT 1B/1D or other receptors related to vasoconstriction. Taken together, DSP-6952 is unlikely to have the potential risk for cardiac ischemia via coronary vasoconstriction due to off-targeted binding to 5-HT receptors, which differs from tegaserod or sumatriptan. Because the effective concentration of approximate 10 μM of tegaserod was much higher in the isolated rabbit coronary arteries than the C max of approximate 9 nM at the recommended therapeutic dose (AppelDingemanse, 2002; Chan et al., 2009) , mechanism for cardiac ischemic potential of tegaserod was followed up. Because the TXA 2 analogue, U-46619, was reported to augment coronary artery contraction induced by sumatriptan (Kapoor et al., 2004) , the effects of U-46619 on that by tegaserod were evaluated. Consequently, the concentration-contractile response curve of tegaserod was shifted to lower concentrations by approximately 100-fold in the presence of 10 −7 to 10 −3 μM of U-46619. These concentrations are comparable to the physiological levels of TXA 2 in humans, and TXA 2 levels were reported to increase in the patients with angina pectoris (Fitzgerald et al., 1986; Tada et al., 1988) . These results suggest that multiple risk factors, including increased TXA 2 levels might contribute to the cardiac ischemic adverse events of tegaserod; however, further studies are needed to clarify the cardiac ischemic potential or the mechanism.
Conclusion
DSP-6952 is a promising GI prokinetic compound with partial 5-HT 4 receptor agonistic activity as well as a favorable cardiovascular safety profile, which are different from other marketed prokinetcis with full 5-HT 4 receptor agonistic activity or off-target binding for hERG channel or other 5-HT receptors.
